Tevimbra (tislelizumab-jsgr) Coverage and Prior Authorization
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0262 alerts
Get alerted when Policy CC-0262 changes without checking for updates manually.
Monitor payer policy activity
This medical drug clinical policy governs prior authorization and medical necessity review for intravenous Tevimbra (tislelizumab-jsgr) in adults and other individuals with specified cancers. Coverage is available only for listed FDA-approved or NCCN-compendial indications when the stated disease, biomarker, treatment-line, combination-therapy, and prior-treatment criteria are met.
The policy added the FDA indication for Tevimbra in combination with Ziihera and fluoropyrimidine- and platinum-containing chemotherapy for HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
The policy added NCCN 2A criteria for Tevimbra with paclitaxel and carboplatin in anal carcinoma.
The policy added NCCN 2A recommendations for classic Hodgkin lymphoma and endometrial carcinoma.
The policy added NCCN criteria for appendiceal cancer and separated small bowel adenocarcinoma criteria from colorectal cancer criteria.
The policy removed HER2 requirements from the esophageal squamous cell carcinoma criteria and removed ECOG requirements from the gastric and gastroesophageal junction criteria.
The policy clarified CLL/SLL eligibility for del(17p)/TP53-mutated disease or disease that is chemotherapy refractory or unable to receive chemoimmunotherapy.
The policy added an FDA indication for Tevimbra in combination with Ziihera for gastric, gastroesophageal junction, and esophageal adenocarcinoma.
The policy added NCCN category 2A criteria for Tevimbra in combination with paclitaxel and carboplatin for anal carcinoma, classic Hodgkin lymphoma, and endometrial carcinoma.
The policy revised criteria for esophageal squamous cell carcinoma, gastric and gastroesophageal junction cancers, chronic lymphocytic leukemia/small lymphocytic lymphoma, anal carcinoma, colorectal cancer, nasopharyngeal cancer, and hepatocellular carcinoma.
The policy added NCCN recommendations for appendiceal cancer, small bowel adenocarcinoma, nasopharyngeal cancer, hepatocellular carcinoma, and other specified malignancies.
The policy replaced HCPCS J3590 and J9999 with HCPCS J9329 and added or revised multiple ICD-10-CM codes during coding reviews.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.